FDA eyes ‘mix and match’ approach for COVID-19 boosters

The U.S. Food and Drug Administration could announce that Americans will be able to get a different COVID-19 vaccine as a booster than the one they originally received, according to a report.
According to the New York Times, the agency is preparing to OK the "mix-and-match" approach instead of endorsing one vaccine over another. However, according to the New York Times, the FDA might note that getting the same vaccine as a booster is preferable.
The National Institutes of Health presented early information to the FDA’s advisers Friday.
The information is from an ongoing study showing it did not matter which vaccine people got versus which booster they got.
All combinations were deemed safe and showed a revved up immune response. Officials say mixing boosters may also provide a strong response to the delta variant.
The announcement by the FDA is likely to come along with the authorization for boosters of the Moderna and Johnson & Johnson shots.
Approval for a third dose of the Pfizer vaccine for Americans was announced last month.
Allowing mixing and matching could help with supply issues and make it easier for those who may have had an adverse reaction to the initial dose try a different shot.
An advisory committee of the Centers for Disease Control and Prevention will take up the booster issue on Thursday. The agency will then issue its own recommendations.